Norroy receives China’s clearance for Phase III study of 177Lu-NYM032

Norroy Bioscience has received approval from the NMPA to start a Phase III clinical trial in China for 177Lu-NYM032, a PSMA-targeted small-molecule radioligand therapy. The trial will be led by Peking Union Medical College Hospital and conducted at several centres in China. Initial clinical results for 177Lu-NYM032 from earlier Phase I/II studies suggested anti-tumour activity and a favourable safety profile. Credit: Premreuthai / Shutterstock.com. Norroy Bioscience has received approval from the National Medical Products Administration (NMPA) to start a Phase III clinical trial in China for 177Lu-NYM032, a prostate-specific membrane antigen (PSMA)-targeted small-molecule radioligand therapy. The study will assess the…

Source: Clinical Trials Arena